SCHEMBL2280832

SCHEMBL2280832

COCOc1cc(OC)ccc1B1OC(C)(C)C(C)(C)O1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SNCA P37840 1/20 0.38
MAPT P10636 3/20 0.37
UCHL1 P09936 1/20 0.37
CYP3A4 P08684 3/20 0.36
ALDH1A1 P00352 3/20 0.36
CYP2D6 P10635 2/20 0.36
TSHR P16473 2/20 0.36
CYP2C19 P33261 2/20 0.36
CYP2C9 P11712 1/20 0.36
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA9 Q16790 2/20 0.36
CA12 O43570 1/20 0.36
CA7 P43166 1/20 0.36
CA14 Q9ULX7 1/20 0.36
BACE1 P56817 1/20 0.36
ROR1 Q01973 1/20 0.36
KDM4E B2RXH2 1/20 0.34
HIF1A Q16665 1/20 0.34
APLNR P35414 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3804866 0.99 SNCA (0.37) SNCAMAPTUCHL1CYP3A4ALDH1A1
SCHEMBL3804868 0.99 SNCA (0.37) SNCAMAPTUCHL1CYP3A4ALDH1A1
SCHEMBL28544224 0.89 CA1 (0.31) UCHL1CA1CA2CA9ROR1
SCHEMBL28934910 0.88 UCHL1 (0.39) SNCAMAPTUCHL1CYP3A4ALDH1A1
SCHEMBL984465 0.87 SNCA (0.37) SNCAUCHL1CYP3A4ALDH1A1CA1
SCHEMBL27224462 0.85 MEN1 (0.32) MAPTUCHL1ALDH1A1HIF1A
SCHEMBL5899720 0.85 CA2 (0.47) SNCAMAPTUCHL1CYP3A4ALDH1A1
SCHEMBL29424578 0.85 CA2 (0.47) SNCAMAPTUCHL1CYP3A4ALDH1A1
SCHEMBL19087000 0.84 CSF1R (0.34) MAPTUCHL1ALDH1A1CYP2C19CYP2C9
SCHEMBL21412319 0.83 UCHL1 (0.31) UCHL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989438-B2 Therapeutic compounds ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2011-08-02 US disclosed
EP-2178886-A1 MACROCYCLIC INDOLE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C INFECTIONS Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. (IT) 2010-04-28 EP disclosed
US-20090048239-A1 Therapeutic compounds MSD ITALIA S.R.L. (IT) 2009-02-19 US disclosed
WO-2009010785-A1 MACROCYCLIC INDOLE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C INFECTIONS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048239-A1 Therapeutic compounds RRP1B, RCE1, CTSZ SNCA 3104/4885MAPT 4543/4885UCHL1 1474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.